|
|
||||||||
Eur J Cardiothorac Surg 2003;23:670-677
© 2003 Elsevier Science NL
Department of Cardiothoracic and Vascular Surgery, University Hospital of North Norway, Breivika, P.O. Box 102, N-9038 Tromsø, Norway
Received 30 September 2002; received in revised form 20 January 2003; accepted 23 January 2003.
* Corresponding author. Tel.: +47-77-626-000/637-338; fax: +47-77-628-298
e-mail: tors{at}fagmed.uit.no
| Abstract |
|---|
|
|
|---|
Key Words: Cardioplegia Energetics Myocardial protection Nicorandil
| 1. Introduction |
|---|
|
|
|---|
The use of ATP-sensitive potassium channel (KATP channel) openers as cardioplegic agents have shown improved myocardial protection in several experimental studies. In the intact animal, the KATP channel opener pinacidil has shown preserved postcardioplegic left ventricular function [5,6]. Two KATP channel subtypes exist in the myocardium, one in the sarcolemma and the other in the inner mitochondrial membrane (mitoKATP) [7]. Activation of surface KATP channels in the myocyte have been proposed to produce cardioprotection via a shortening of the cardiac action potential and membrane hyperpolarisation, both of which would lead to reduced calcium overload during ischemia or reperfusion and a preservation of ATP [8]. The mitoKATP channel is central in cardioprotection during ischemia or reperfusion [9] but the mechanisms for this protection are still unknown [10].
Nicorandil is a nitrate and a KATP channel opener [11] and it activates both sarcolemmal and mitochondrial KATP channels. It is approved for use in humans and has been shown to protect the myocardium against ischemic- and reperfusion injury as an additive to cardioplegia [9,12,13]. Nicorandil in Krebs-Henseleit solution has been shown in isolated rabbit hearts to give an effective cardioplegia [14] and has been shown in a rat model to mimic the cardioprotective effects of preconditioning [15].
Nicorandil was in this study used as sole cardioplegic agent and compared with the two more traditional forms of cardioplegia, cold hyperkalemic crystalloid and cold hyperkalemic blood cardioplegia. By exchanging potassium with the KATP channel opener nicorandil we hypothesised improved preservation of myocardial efficiency in oxygen to mechanical work transfer after cardioplegia.
| 2. Material and methods |
|---|
|
|
|---|
2.1.2. Instrumentation
After a median sternotomy, the pericardium was incised and the left hemiazygos vein was ligated to avoid systemic blood into the coronary sinus. Ultrasonic transit-time probes (Cardio-Med CM-4000, Medi-Stim AS, Norway) were placed on the pulmonary artery and on the right, the left anterior descending and the circumflex coronary arteries for cardiac output (CO) and myocardial blood flow (MBF) measurements. Cardiac venous blood samples were obtained from a 16 G catheter in the coronary sinus. To transiently reduce left ventricular preload, a 7 F balloon catheter (Sorin Biomedical, Italy) was placed in the inferior caval vein. A 7 F, 12 electrode, dualfield combined microtip and conductance catheter (Sentron, CD Leycom, The Netherlands) for continuous measurements of left ventricular pressures and volumes was introduced into the left ventricle through the left carotid artery. A 22 G catheter was placed in the pulmonary artery for monitoring of mean pulmonary artery pressure and injection of hypertonic saline for parallel volume measurements. A blood prime of fresh porcine blood from a cross-matched donor pig and 15 000 IU/l Heparin was circulated at 37°C in a membrane oxygenator (Monolyth, Sorin Biomedical, Italy) using a centrifugal pump (Biomedicus, MN). After baseline measurements, biopsies, blood collection and full heparinisation (activated clotting time >480 s), the left brachiocephalic artery was cannulated and venous drainage obtained from a cavoatrial cannula. A cardioplegic cannula with a side branch for pressure monitoring was placed in the ascending aorta. The conductance catheter was temporarily withdrawn and cardiopulmonary bypass (CPB) initiated. The aorta was cross-clamped for 60 min and the left ventricle vented through the apex. The myocardial temperature was measured with a myocardial probe connected to a thermistor (COM-1, American Edwards Laboratories, CA). Cardiac biopsies were taken at baseline and at the end of the experiment (14Ga Tru-Cut Biopsy Needle, Pharmaseal, IL) and analysed for water content using the microgravity method described by Mehlhorn [16].
2.2. Protocol
2.2.1. Experimental protocol
After baseline measurements 29 pigs were randomised to receive standard potassium-magnesium crystalloid cardioplegia or two sorts hypothermic blood cardioplegia, either hyperkalemic blood cardioplegia, or blood cardioplegia in which the ATP-sensitive potassium channel opener nicorandil replaced the potassium. All forms of cardioplegia were given antegradely through the aortic root cannula and intermittently, cardiac arrest was initiated with 500 ml followed by 200 ml cardioplegia every 20th min. The infusion pressure measured at the aortic root was kept between 50 and 80 mmHg.
Blood cardioplegia was cooled to 10°C on a separate blood cardioplegia system (Shiley BCD, Phizer, CA), and administered antegradely. Cardioplegic solutions were added using an infusion pump (STC 521, Therumo, Japan). The compositions of cardioplegic solutions are outlined in Table 1. Hyperkalemic blood cardioplegia was prepared as described by Menasché [17]. Topical hypothermia was applied when necessary to maintain myocardial temperature below 18°C. The hearts underwent 60 min of ischemic arrest before the aortic cross-clamp was released. Weaning from CPB was tried 20 min after cross-clamp release. If necessary, animals were allowed another 20 min of support before CPB was terminated. The first set of postplegic measurements was sampled 60 min after cross-clamp release. The last set of measurements was sampled following another hour of reperfusion off pump. Only pigs that were successfully weaned from CPB without use of inotropic agents were included in the study.
|
) was measured using a cuvette designed for the conductance equipment. Parallel volume was calculated by plotting values of end-systolic parallel conductance versus values from the preceding end-diastole using at least four consecutive beats with increasing conductance after injection of 4 ml 10% NaCl in the pulmonary artery. Myocardial energetics were assessed at baseline and 2 h after cross-clamp release, using four or more different afterloads. Cardiac output, arterial pressure and coronary flow were allowed to stabilise before the simultaneous collection of left ventricular pressure-volume loops and blood gas samples from the descending aorta and coronary sinus. Haemoglobin (Hb) and aortic and coronary sinus O2 saturation were measured using a blood gas analyser (Ciron Diagnostics, Ciba, MA). Respiratory influence on hemodynamics was avoided by disconnecting the respirator during file sampling.
2.2.3. Calculations
The conductance catheter technique has been described earlier [18]. Briefly, intraventricular volume (V(t)) was calculated from segments of intraventricular blood conductances, using the formula:
![]() |
is the slope factor relating conductance volume to an independent volume estimation, L is the interelectrode distance,
is blood resistivity, G(t) is the sum of segmental conductances and Gp is parallel conductance. The slope factor
was calculated by comparing cardiac output from the pulmonary artery transit-time flow probe with cardiac output from the conductance catheter. The pressure-volume calculations were done by the analysis software of the Conduct PC package after examination of the pressure-volume loops. Left ventricular contractility was assessed by the slope (Mw) of Preload Recruitable Stroke Work (PRSW), which serves as a load- and heart rate independent index of myocardial contractility. The correlation coefficient for all Mw was 0.94 (SD 0.1) and at least ten consecutive beats were recorded during vena cava occlusions (VCO). End-diastolic stiffness was quantified by the end-diastolic pressure-volume relationship, according to the equation: Ped=
xe(ßxVed), where ß describes diastolic stiffness. Diastolic function was also assessed by the derivative of pressure decay with respect to time and the time constant of relaxation, tau, both calculated by the CPC software. In this software, tau is calculated as the time from dPdtmin until pressure reaches half the value at dPdtmin. Pressure-volume area (PVA, in mmHgxml) represent the total mechanical work as described by Suga and colleagues [19] and was calculated as: PVA=[SW+(Pesx(Ves-V0)/2)-(Pedx(Ves-V0)/2)]1.33x10-4 J mmHg-1 ml-1, where Pes and Ves is end systolic pressure and volume, respectively. The V0 was calculated from the extrapolated x-intercept from the curvilinear slope of the end-systolic pressure-volume relationship (Ees) during VCO, and Ped is end diastolic pressure. Left ventricular coronary blood flow (LVCBF) was estimated as left ventricular weight/heart weight times coronary blood flow. Left ventricular oxygen consumption was calculated by MVO2=(LVCBFxavdO2xHbx1.39)/HRx20.2, where MVO2 is left ventricular myocardial oxygen consumption, avdO2 is difference between aortic and myocardial venous oxygen saturation, Hb is haemoglobin in g/ml, 1.39 is a constant in ml O2/g Hb, HR is heart rate and 20.2 is a constant in Joule/ml O2. MVO2 relates to PVA in a linear way and the y-intercept is assumed to be equivalent to directly determined Unloaded MVO2 [19].
2.3. Statistics
All results are expressed as mean±1 SD. Normality of data was analysed with normal score plots of residuals. Data were analysed using analysis of variance for repeated measures (RANOVA). Delta values, calculated as the difference between baseline and later measurements, were used as the response. In analysis of ventricular energetics one way analysis of variance were performed. Tukey or Dunnett t post hoc tests were used to analyse pairwise group differences. The analyses were performed using the statistical software package SPSS (SPSS10.0©, SPSS Inc., IL).
| 3. Results |
|---|
|
|
|---|
Four animals in the nicorandil group and one animal in the crystalloid group regained sinus rhythm spontaneously during reperfusion, all other animals had to be electroconverted.
Tables 24 give haemodynamic and mechanical parameters. Heart rate, systemic vascular resistance (SVR) and MBF increased after cardioplegic arrest but there were no significant group differences. Heart rate was higher at baseline in the nicorandil group compared with hyperkalemic blood (P=0.006) and crystalloid (P=0.017) and mean arterial pressure (MAP) was significantly higher at baseline in the nicorandil group compared with crystalloid (P=0.006). There were no other differences in baseline values.
|
|
|
) and peak negative dP/dt declined in all groups with no group differences indicating prolonged early relaxation or, impaired active diastolic function.
|
|
|
3.4. Myocardial blood flow
All groups had an increase in MBF after cardioplegia as shown in Table 2. The MBF in the hyperkalemic blood group and in the nicorandil group increased more than in the crystalloid group 1 h after cross-clamp release. After reperfusion for another hour there were no significant differences in MBF between groups.
| 4. Discussion |
|---|
|
|
|---|
The major findings in this study are preserved mechanoenergetics and contractility after cardioplegia with the ATP-sensitive potassium channel opener (KATP channel) nicorandil. KATP channels are present in both sarcolemma and in mitochondrias and the cardioprotective effects have mostly been attributed to mitoKATP [20]. Hypothermia, activation of KATP channels with nicorandil and procaine in the bolus dose was sufficient to promptly induce and maintain a stable cardiac arrest.
According to Suga, the slope of the total MVO2-PVA relationship describes efficiency in all processes converting oxygen to mechanical work: (1) oxygen-to-ATP conversion; and (2) ATP consumption in myofibrillar contraction [19]. The unaltered slope of the MVO2-PVA relationship after cardioplegia in the nicorandil group shows preserved efficiency in oxygen to mechanical work transfer in this group. In the other groups there was a substantial elevation of the slope of the MVO2-PVA relationship and hence a reduced efficiency on one or two of the above-mentioned steps after cardioplegia.
The mechanisms of mitochondrial protection is still debated and several hypotheses are proposed, including uncoupling, increased reactive oxygen species production and depolarisation leading to reduced mitochondrial calcium uptake [13,21]. One hypothesis is that opening of the mitoKATP maintains the architecture of the mitochondrial inter-membrane space challenged by ischemia, thereby preserving outer membrane permeability, the function of mitochondrial creatine kinase and subsequently preserve cellular ATP levels [22]. Protection of mitochondrias by nicorandil cardioplegia could explain the observed beneficial effect opening of mitoKATP had on myocardial energetics in this study.
Initially we wanted a longer period of cardiac arrest but 60 min of global ischemia was the absolute maximum for the hearts of the crystalloid group to be able to complete the protocol. The fact that three animals in the crystalloid group could not be weaned from CPB demonstrated this. Crystalloid cardioplegia usually offers adequate cardioprotection when patients are at low risk and the ischemic times are kept below 90 min [23]. On the other hand, there is a substantial risk of at least a temporary reduction in contractility also in patients after cardiac surgery using potassium cardioplegia [24]. Potassium-induced cardiac arrest facilitates intracellular movement of calcium ions and the exportation of this calcium load during reperfusion may contribute to the reduced efficiency in the postischemic heart [25].
Elevated tissue water and increased myocardial oxygen demand during reperfusion have previously been described as probable drawbacks when using another KATP channel opener, pinacidil, in blood cardioplegia [26]. In our study, neither oedema nor increased oxygen demand represented a problem with nicorandil in cold blood. The water content increased similarly in all groups as revealed by the microgravity method. Myocardial blood flow increased more after hyperkalemic blood and nicorandil cardioplegia but the unchanged slope of the MVO2-PVA relationship in the nicorandil group denotes preserved efficiency. Whether or not the impaired hyperemia in the crystalloid group represents a detrimental effect on vascular endothelium is not answered by our study. Previous authors have suggested that the KATP channel opener pinacidil has to be given continuously as cardioplegia in blood to achieve systolic recovery [27]. Our study demonstrates that we may use nicorandil intermittently and still preserve systolic function.
Nicorandil is approved for human use and it has been used as an antianginal agent in nearly two decades. Nicorandil is a drug with both nitrate-like and KATP channel activating properties [11]. The half-life is about 1 h and the drug is excreted in the kidneys. Possible systemic effects are increased heart rate and dilatation of the vascular bed. Heart rate was increased and systemic vascular resistance was lowered but we found no differences between groups. This indicates minimal systemic influence of nicorandil, probably due to the low doses necessary and the administration of the drug directly to the heart.
Nicorandil given intermittently in cold blood as sole cardioplegic agent was feasible in the intact animal, providing reliable and rapid mechanical arrest. This regimen preserved mechanoenergetics and systolic and diastolic functions markedly better than the two most common methods of cardioprotection used today. The results of this study strongly warrant further investigations of this alternative to hyperkalemic cardioplegia both experimentally and clinically.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
E. Aarsaether, T. A. Stenberg, O. Jakobsen, and R. Busund Mechanoenergetic function and troponin T release following cardioplegic arrest induced by St Thomas' and histidine-tryptophan-ketoglutarate cardioplegia - an experimental comparative study in pigs Interactive CardioVascular and Thoracic Surgery, October 1, 2009; 9(4): 635 - 639. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Steensrud, S. Muller, P. C. Endresen, and D. G. Sorlie Clinical testing of nicorandil supplemented normokalemic cardioplegic solution Interactive CardioVascular and Thoracic Surgery, October 1, 2006; 5(5): 521 - 525. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Steensrud, O. Jakobsen, K. Ytrehus, and D. G. Sorlie Contractile recovery of heart muscle after hypothermic hypoxia is improved by nicorandil via mitochondrial K(ATP) channels. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 256 - 262. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-Y. Dong, M. Wu, A. P.C. Yim, and G.-W. He Hypoxia-Reoxygenation, St. Thomas Cardioplegic Solution, and Nicorandil on Endothelium-derived Hyperpolarizing Factor in Coronary Microarteries Ann. Thorac. Surg., November 1, 2005; 80(5): 1803 - 1811. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Yang, R.-Z. Zhang, A. P.C. Yim, and G.-W. He Release of Nitric Oxide and Endothelium-Derived Hyperpolarizing Factor (EDHF) in Porcine Coronary Arteries Exposed to Hyperkalemia: Effect of Nicorandil Ann. Thorac. Surg., June 1, 2005; 79(6): 2065 - 2071. [Abstract] [Full Text] [PDF] |
||||
![]() |
O.-J. How, E. Aasum, S. Kunnathu, D. L. Severson, E. S. P. Myhre, and T. S. Larsen Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2979 - H2985. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Lin, Z.-W. Zhang, Q.-X. Xiong, C.-M. Cao, Q. Shu, I. C. Bruce, and Q. Xia Pinacidil improves contractile function and intracellular calcium handling in isolated cardiac myocytes exposed to simulated cardioplegic arrest Ann. Thorac. Surg., September 1, 2004; 78(3): 970 - 975. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Chambers Nicorandil cardioplegia or procaine cardioplegia? Eur. J. Cardiothorac. Surg., October 1, 2003; 24(4): 670 - 670. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |